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Abstract
Orally administered 5-aminolevulinic acid (5-ALA), which was approved in the United States in 2017, is
preferentially metabolized by malignant glioma cells into protoporphyrin IX and enhances tumor
visualization when using a blue light filter on an operating microscope. Photosensitivity after 5-ALA
administration is a known side effect, but a photosensitivity reaction from operating room lights has not yet
been documented. We report the case of a 56-year-old man with a history of previous resection of a grade II
astrocytoma who presented with imaging concerning for tumor recurrence and possible malignant
transformation. Repeat surgical resection utilized 5-ALA. Soon after the surgery, he developed reddening of
his skin, particularly over the right side of his head and neck, with blistering and peeling in a distribution
that was particularly exposed to operating room lights during surgery. No other areas of his skin
experienced the same redness, blistering, or peeling. Topical lotions were applied and the skin changes
resolved spontaneously over weeks. Significant photosensitivity after administration of oral 5-ALA is a rare
complication, but neurosurgeons who perform fluorescence-guided tumor resection should remain
cognizant of its potential association with exposure to intense light, including in the operating room.
Phototoxicity typically is self-limited, but awareness is important to minimize its occurrence.
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Introduction
Five-aminolevulinic acid (5-ALA) is an orally administered intraoperative optical imaging agent that was
approved by the United States Food and Drug Administration in June 2017 for patients with suspected World
Health Organization (WHO) grade III or IV gliomas [1]. It has been approved in Europe since 2007.
Biochemically, 5-ALA is a precursor of protoporphyrin IX in the heme biosynthesis pathway. Its utility as a
tumor-specific fluorescent agent is based on the idea that malignant gliomas selectively uptake 5-ALA via
the disrupted blood-brain barrier and metabolize it to protoporphyrin IX. Once produced and retained in
glioma cells, protoporphyrin IX fluoresces red/pink when exposed to 370-440 nm wavelength blue light, and
this fluorescence can be viewed through a specialized filter [2]. Both eliciting and viewing tumor
fluorescence can be accomplished with specially equipped neurosurgical microscopes [2].
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Previous investigations, including randomized prospective trials, have shown that 5-ALA can increase the
extent of resected tumor and progression-free survival compared to traditional microsurgery without
increase in neurological deficits [1,3]. Consequently, 5-ALA is a widely used surgical adjunct in Europe and
Asia and has become increasingly more common in the United States since its approval. Side effects of 5ALA are very rare [4,5], but photosensitization has been associated with its use, typically within 24 hours
after administration [6]. However, photosensitivity reactions after oral 5-ALA administration have not yet
been documented as occurring secondary to operating room lights. Here, we report the case of a patient who
developed such a photosensitivity reaction after oral 5-ALA administration for resection of a malignant
glioma.

Case Presentation
A 56-year-old man with a history of a WHO grade II astrocytoma for which a right posterior temporal lobe
resection (without 5-ALA as it had not yet been approved in the United States) had been performed 15 years
previously at another institution presented with an episode of left arm stiffening, aphasia, and altered
mental status that was concerning for a new-onset seizure. Magnetic resonance imaging (MRI) studies
demonstrated an enlarging mass with enhancing foci adjacent to the previous resection cavity, likely
representing tumor recurrence and malignant transformation (Figure 1). He was referred to our institution
for further management, and surgical resection was recommended.
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FIGURE 1: Preoperative T1-weighted MRI with contrast demonstrating
an enhancing focus (red arrow) in the right posterior temporal lobe
adjacent to the resection cavity for the patient’s prior grade II
astrocytoma (A). Preoperative FLAIR MRI demonstrating hyperintensity
in the right posterior temporal lobe, which had increased in size from
previous studies (B). Pathology obtained during surgery confirmed
WHO grade III anaplastic astrocytoma.
MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery

The patient underwent a repeat right temporoparietal craniotomy. In accordance with the hospital protocol,
he was given oral 5-ALA (GleolanTM NX Development Corporation, Lexington, KY, USA) at the standard
dose of 20 mg/kg three hours preoperatively, which successfully yielded tumor fluorescence when viewed
with the specialized blue filter on the operative microscope (Zeiss Pentero microscope, Carl Zeiss Meditec,
Inc., Dublin, CA, USA) (Figure 2). The tumor was resected until the surgeon felt that maximal resection had
been achieved. To confirm this extent of resection, intraoperative MRI (iMRI) studies were obtained using a
1.5 Tesla movable iMRI device (IMRIS, Inc., Minnetonka, MN, USA). These images demonstrated resection of
all enhancements with minimal residual T2/fluid-attenuated inversion recovery abnormality in the posterior
aspect of the resection cavity, which was subsequently resected prior to closure. The patient tolerated
surgery well with no new neurological deficits and was discharged on postoperative day two. Surgical
pathology confirmed a WHO grade III anaplastic astrocytoma with an isocitrate dehydrogenase 1 R132H
point mutation, and the patient was referred for chemotherapy and radiation therapy.
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FIGURE 2: Tumor that was resected with the aid of 5-ALA (pink color).
The tumor demonstrates red/pink fluorescence when the appropriate
blue light and filter are used with the operating microscope.
5-ALA, 5-aminolevulinic acid

During his hospitalization, in the early postoperative period, the patient developed mild diffuse erythema of
his skin, including on his extremities and torso. The intensity of the erythema was most severe on the right
side of his head and neck where there was associated blistering and peeling of the skin in a distribution
defined by the region of the surgical field (Figure 3). Notably, the right side of his head and neck were the
only areas of his body that had been exposed to the intense surgical lights (Berchtold Chromophare halogen
lights, Stryker, Kalamazoo, MI, USA) in the operating room. Similar erythema and blistering was not
observed on any other part of his body, including the left side of his head and neck, which had remained
covered during surgery. He had not been exposed to any sources of natural light during his hospitalization
and had been kept in a dark room postoperatively. No reddening of skin had been observed before surgery.
He had no renal disease that may have compromised excretion of 5-ALA. The blistering on his head and
neck persisted until his one-week postsurgical follow-up visit. He never experienced fever, rashes, or other
symptoms during this time period. He treated the blisters with over-the-counter lotion and they resolved
uneventfully over a few weeks. Consultation with dermatology was recommended to the patient, but he did
not pursue it as the skin changes were resolving spontaneously.
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FIGURE 3: Image of the right side of the patient’s head and neck taken
at his one-week follow-up visit demonstrating a healing surgical
incision as well as skin erythema, blistering, and peeling. Of note, the
worst of the skin erythema and the blistering and peeling were only
seen on the right side of his head/neck, which were the areas of his
body that had been exposed to surgical lights in the operating room.

Discussion
Photosensitivity reactions are a rare but acknowledged side effect of oral 5-ALA administration, and patients
are generally advised to avoid direct light for 24-48 hours after the agent is administered. The link between
5-ALA and tissue photosensitization has been well-established, as topical or oral 5-ALA has been used in
multiple fields to enhance photodynamic therapy for treatment of lesions of the skin, oral mucosa, and
esophagus [7-9]. Here, we report an instance in which a patient developed a photosensitivity reaction on
areas of his body that had been exposed to operating room lights. To the authors’ knowledge, this is the first
such reported case related to oral 5-ALA. This report should reinforce the need to warn patients and families
about photosensitivity side effects that, while not fatal or permanent, could be distressing if unanticipated.
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Multiple past reports have been published detailing photosensitivity reactions that resulted from operating
room light exposure, but these concerned patients who had erythropoietic protoporphyria [10,11] or who
were preoperatively administered methylene blue [12,13]. Erythropoietic protoporphyria is an X-linked
disorder of porphyria metabolism that leads to the accumulation of protoporphyrin IX in cells of erythroid
lineage [14]. When these cells are exposed to light at 320-595 nm wavelength, the high protoporphyrin IX
levels lead to the generation of reactive oxygen species that mediate phototoxic effects on the skin [14,15].
Graham-Brown and Ilchyshyn [15] reported a case in which a patient with this disorder underwent surgery
for the creation of a left arm arteriovenous fistula. The day after the surgery, the patient noted erythema and
edema of the skin that had been exposed to operating room lights. No other areas of his body exhibited
these findings. Herbert et al. [10] and McGuire et al. [11] detailed instances in which patients receiving liver
transplants for erythropoietic protoporphyria experienced skin phototoxicity in areas that had remained
uncovered during surgery.
Methylene blue is a dye that may be given intravenously during parathyroid gland surgery to identify
abnormal glands. Upon exposure to light between 500-700 nm, the dye releases reactive oxygen species that
can cause tissue damage [12]. Maguire et al. [12] presented two cases of patients who underwent
parathyroidectomy using methylene blue. In both cases, the patient developed skin erythema and vesicles
localized to the anterior neck and upper chest, areas that had been exposed during surgery. No erythema or
other skin changes were noted in areas that had been covered. Lambrecht et al. [13] reported the case of a
woman who developed a sharply demarcated photosensitivity reaction of the skin on her neck that was
exposed to operating room lights. Of note, this case occurred right after the authors’ institution changed
from halogen lamps to light-emitting diode (LED) lamps in the operating room. After emission spectrum
analyses, these LED lights were found to produce more intense light in both the blue spectrum (430-490 nm)
and the excitation spectrum for methylene blue (500-700 nm). The authors hypothesized that the
combination of the photodynamic therapy-like effects of blue spectrum light and the photoexcitation of
methylene blue contributed to skin phototoxicity.
Past reports examining photosensitivity after oral 5-ALA administration for glioma resection have found
that this complication is quite rare, occurring in potentially <1% of patients [3,16]. The mechanism of 5ALA-induced photosensitivity is similar to that of erythropoietic protoporphyrin. In addition to being taken
up by malignant glioma cells, 5-ALA accumulates in skin cells, which convert it to protoporphyrin IX. The
same light-induced generation of reactive oxygen species then leads to cytotoxic damage and the clinical
signs and symptoms of photosensitization [17]. At the normal administered dose of 20 mg/kg body weight, 5ALA reaches peak plasma levels at between 30 minutes and two hours, and return to baseline after 24 hours
[16]. Protoporphyrin IX reaches maximum plasma levels in four hours, begins to decline over the next 20
hours, and is almost completely eliminated by 48 hours [18]. A pharmacokinetic study of 5-ALA found that
an oral dose of 40 mg/kg body weight (twice the dose used for glioma resection) reached peak levels in the
skin at a mean time of 6-10 hours, depending on the location, as measured by skin fluorescence [19]. After 40
hours, the average level of 5-ALA was 5% of the maximum.
Therefore, it is physiologically plausible that the patient in this report was rendered sufficiently
photosensitized by oral 5-ALA to have a photosensitivity reaction to operating room lights. This hypothesis
is further supported by the fact that only the skin that had been exposed to the lights in the operating room
experienced the most severe erythema as well as blistering and peeling. Moreover, he did not have any other
signs or symptoms to support a different medication-induced systemic reaction to 5-ALA (e.g., StevensJohnson syndrome). The skin peeling resolved with over-the-counter treatment, and the patient did not
necessitate further medical treatment. Halogen lights, as used in this operation, produce more light towards
the warm and infrared portions of the electromagnetic spectrum, and a wavelength of 635 nm is typically
used for photodynamic therapy [8,9]. Perhaps this complication could have been avoided with diodes that
emitted less light of these wavelengths, but this is difficult to know for sure. Specialized filters may be
placed over operating room lights to eliminate phototoxic injury, though these would likely not be beneficial
for the vast majority of cases that use 5-ALA.
It would be interesting to examine whether the standard 20 mg/kg dose of oral 5-ALA is necessary in all
patients to achieve acceptable tumor fluorescence and maximal extent of resection or whether lower doses
may yield satisfactory tumor detection while reducing the chances of photosensitivity reactions, as
witnessed in this patient. Haj-Hosseini et al. [20] found that low-dose 5-ALA (5 mg/kg, administered orally)
was equally reliable for tumor detection as the standard dosing, though the standard-dose cohort had higher
intraoperative tumor fluorescence. Of note, no patients who were administered the lower dose were found to
have protoporphyrin IX in their skin while it was detected in the skin of nearly every patient in the
standard-dose cohort [20]. Further studies should examine the dosing of 5-ALA that is required for adequate
tumor detection, as well as patient-specific factors that may affect the efficacy of these lower doses to
minimize future incidences of photosensitivity. It is also not well-known if multiple doses of 5-ALA (e.g.,
across multiple tumor resections) increase the risk of photosensitivity reactions.

Conclusions
Photosensitivity after administration of oral 5-ALA is a rare complication, and until now a report of 5-ALAassociated photosensitivity from operating room lights has never been published. Nonetheless,
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neurosurgeons who perform fluorescence-guided tumor resection should remain cognizant of this potential
side effect. As 5-ALA becomes a more popular surgical adjunct for glioma resections, events like this will
become more common. This report offers a practical teaching point for anyone involved in the care of
patients who have undergone surgical resection utilizing this imaging agent. After administration of oral 5ALA, the phototoxicity from exposure to light, particularly the intense lights of the operating room, may
cause a significant skin reaction. Typically, this is a self-limited reaction, but minimizing light exposure is
important to both reduce the chances of such a reaction as well as to avoid more serious skin damage or
wound healing problems. Precautions may be taken such as shining the lights away from the patient until the
patient has been fully draped or positioning the lights at the maximum distance from the patient that still
offers adequate illumination.
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